<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Clinical   Health and Educational Psych</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/551CC5B3-C617-457F-874F-1540EC096FEC"><gtr:id>551CC5B3-C617-457F-874F-1540EC096FEC</gtr:id><gtr:firstName>Gianluca</gtr:firstName><gtr:surname>Baio</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B353C72E-60A1-419D-9AF5-A8DBF60C7D77"><gtr:id>B353C72E-60A1-419D-9AF5-A8DBF60C7D77</gtr:id><gtr:firstName>Celia</gtr:firstName><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DF88960C-E842-4ECC-90A9-C07E07EECBE0"><gtr:id>DF88960C-E842-4ECC-90A9-C07E07EECBE0</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:otherNames>Parsons</gtr:otherNames><gtr:surname>Freeman</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BEDA41E9-DB2B-47F2-88D5-BAB4A38D2757"><gtr:id>BEDA41E9-DB2B-47F2-88D5-BAB4A38D2757</gtr:id><gtr:firstName>Helen</gtr:firstName><gtr:otherNames>Valerie</gtr:otherNames><gtr:surname>Curran</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/504F088E-0E6B-4549-97DC-62154A607BCB"><gtr:id>504F088E-0E6B-4549-97DC-62154A607BCB</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:surname>Kinghorn</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK015524%2F1"><gtr:id>0264FAF2-1CE1-4894-BE33-C53A27E49217</gtr:id><gtr:title>Cannabidiol: a novel treatment for cannabis dependence?</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K015524/1</gtr:grantReference><gtr:abstractText>In Europe, 1% of all adults and nearly 2% of 14-17 year olds are addicted to cannabis. Rates of cannabis dependence have increased markedly over recent years alongside changes in the ingredients of cannabis available on the market (increasing skunk or sinsemilla with high THC and lacking CBD). Among UK first-time drug treatment clients, cannabis is now the primary addiction in 28% of those entering drug treatment, second only to heroin (41%). At present, clinicians rely on psychological treatments which have very limited effectiveness. There is no pharmacological treatment for cannabis addiction. If we found a safe, effective medicine this could improve treatment in a similar way that various medicines have improved rates of stopping tobacco use. It would also impact on educational/vocational achievement and illegal behaviour, and reduce young people's risks of cannabis-associated mental health problems (e.g. schizophrenia, depression). 
Converging preclinical and human research suggests cannabidiol (CBD) to be a highly promising treatment, with excellent tolerability and safety. One of the key consequences of cannabis withdrawal is anxiety and CBD reduces anxiety. CBD has shown promising pro-cognitive and neuroprotective effects which may reverse some of the cognitive deficits associated with cannabis dependence. Our recent research has shown that cannabis dependence is more common in those using 'skunk'. Other data suggest a mechanism by which CBD may be protective against cannabis dependence. A key feature of addiction is that an addict's attention is strongly drawn to cues related to the drug abused over and above other cues and this makes it hard to stop use. Animal evidence suggests that CBD can reduce the ability of drug cues to cause relapse to heroin. In people dependent on cannabis, we have found that CBD reduced attention grabbing by cannabis-related pictures. After CBD, cannabis users rated cannabis pictures as less pleasurable. Thus CBD may reduce the motivating power of drug cues. Overall, evidence now suggests that CBD is a logical treatment for cannabis dependence, by targeting key mechanisms both in dependence and equally importantly, cannabis withdrawal symptoms. 
This project's objectives are first to determine the optimal dose of CBD and then to evaluate its efficacy in treating cannabis dependence.
Design: participants will be 16-26 year olds who meet clinical criteria for cannabis dependence. Stage 1 is a dose-finding study comparing 28 days' treatment with CBD 200, 400, 800mg or matched placebo. Data will be independently reviewed during interim analyses to identify the Most Effective Dose based on measures of changes in cannabis use and withdrawal symptoms. Stage 2 will then expand existing group numbers by allocating new participants to either MEDmg or placebo until there are 60 in each group. Success criteria at Stage 2 include more individuals in the CBD than the placebo group being abstinent or non-dependent and significantly reduced intensity of cannabis withdrawal symptoms. We also predict that those given CBD treatment will show improvements in memory, psychological well-being and days in work/education. 
Application: More people are dependent on cannabis than any other illicit drug - at least 18 million worldwide. The demand for cannabis treatment has more than doubled since 2001 (UNODC World Drug Report 2010). An effective pharmacological treatment would therefore be a major benefit to mental and physical health. It would also impact upon associated psychological and social consequences of cannabis addiction. Benefits would additionally accrue in a reduction of the acute harms associated with cannabis (e.g. anxiety, psychosis-like effects, increased risk of road traffic accidents). The success of this study would provide a very strong impetus for a large scale clinical trial.</gtr:abstractText><gtr:technicalSummary>Background: In Europe 1% of all adults and nearly 2% of 14-17 year olds are addicted to cannabis and 28% of all new drug treatment admissions are now for primary cannabis dependence. There is no medication for cannabis dependence. An effective treatment would impact significantly on medical and legal costs, on young people's educational achievement and their risk of mental health problems. 
Proposed solution: Based on a strong preclinical rationale, our own extensive human data and the importance of the endocannabinoid system in reward and addiction, cannabidiol (CBD) is a highly promising treatment which has excellent tolerability and safety. 
Objectives: To determine the optimal dose of CBD and its efficacy in the treatment of cannabis dependence.
Design: Stage 1 (dose-finding study) will randomly allocate 16-26 year olds who meet DSM criteria for cannabis dependence to parallel groups administered oral CBD 200, 400, 800mg or matched placebo for 28 days. Independent data review at specified recruitment points will identify doses of interest based on significant reductions in urinary THC-COOH, self-reported cannabis use and withdrawal intensity. If Stage 1 successfuly identifies a Most Effective Dose (MEDmg) of CBD, Stage 2 will expand existing group numbers by allocating new participants to MEDmg or placebo (total N=120). Primary success criteria include: more abstinent cannabis users (ideal criterion), more non-dependent users (acceptable criterion) and reduced withdrawal intensity in the CBD than placebo group. Secondary criteria include improved memory, psychological well-being and days in work/education. 
Application/exploitation: The findings would have broad application given the world wide prevalence of dependent cannabis use and associated medical, psychological and social consequences. The success of this study would provide a very strong impetus for a large scale clinical trial.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit from this research?

Policy makers: currently there are reviews of drug policy occurring in both the House of Commons and the House of Lords. A pharmacological treatment for cannabis dependence may well influence drug policy in terms of debates about decriminalisation or licensing cannabis use. In the USA, policy makers may use this research in debating the continuation or not of medical uses of marijuana. Within the UK, users of this research would be the government's Advisory Council on the Misuse of Drugs and the Independent Scientific Committee on Drugs. 

Wider public: cannabis is a public health issue across the world and so the findings of this project have potential for global impact. Those addicted to cannabis will be the major users of this research. Dependent cannabis use by younger people can impact negatively upon their families and their schools/colleges and these may be indirect beneficiaries. Cannabis remains a large problem for policing and the legal system. The probationary/legal system could be users of this research in terms of advocating more effective treatment orders. 

Charities: there are various charities concerned with the use of drugs who will use outputs from this project. For example, the charity DrugScope provides educational materials for school pupils and their teachers and these could encourage more problematic cannabis users to seek help given an effective pharmacological treatment. 

Commercial private sector: companies manufacturing cannabidiol would be users of this research. They would also benefit in terms of increased understanding of the effects of CBD treatment on the brain's endogenous cannabinoid system which would be very important to the development of new cannabinoid targets, some of which are now in the early stages of development.


How might they benefit?
Potential to contribute to the nation's health and wealth: the marked prevalence of cannabis use makes it a public health issue and if successful this project will make a significant contribution to the nation's health. It will also have impact on wealth in terms of fewer days absent from education/work and this combined with improved neurocognitive function should enhance achievement and productivity. Quality of life of individuals with the addiction and their families would be improved by successful pharmacological treatment.

Increasing the effectiveness of public services and policy: the main users will be NHS Drug Treatment Services and treatment provision within the charitable and private sectors.
Timescales for the benefits to be realized: the success of this project would lead to a large scale randomized clinical trial which, if also successful, would mean that benefits to the target population of cannabis dependent individuals could be realized within 3 years following completion of the present project.

What research and professional skills of staff working on the project will be gained? We anticipate a wide range of generic research skills will be acquired by the post-doc and RA as well as generic communication skills (via peer-reviewed articles, conference abstracts, oral presentations to a range of academic and non-academic audiences).</gtr:potentialImpactText><gtr:fund><gtr:end>2017-10-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-01-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1115634</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Sciences Centre (CSC)</gtr:department><gtr:description>Sensitivity to acute effects of cannabis: PET and FMRI analysis</gtr:description><gtr:id>DE9FDA6A-EC8A-4D34-B521-BADEA62445A6</gtr:id><gtr:impact>There have been two publications (doi: 10.1007/s00213-014-3523-4 and 10.1016/j.biopsych.2013.05.027)</gtr:impact><gtr:outcomeId>JN5fJbQ2omN-1</gtr:outcomeId><gtr:partnerContribution>Brain scanning expertise and use of scanner</gtr:partnerContribution><gtr:piContribution>Recruitment of participants who are highly sensitive to acute cannabinoid psychotomimetic effects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Early Phase Clinical Trials Workshop, MRC Clinical Trials Unit (London, November 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FDC72A73-FDE6-4C4B-AECB-2E31DB20DA88</gtr:id><gtr:impact>Talk by TF on 'Risk evaluation: monitoring on a CBD trial' Early Phase Clinical Trials Workshop, MRC Clinical Trials Unit, London, November 2015. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd7579eaf7e4.90898345</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at The London Salon on Cannabis: Medicine, madness and Pleasure (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E72E0F41-DEA2-4217-8A58-D67688ABC8B2</gtr:id><gtr:impact>Invited speaker at The London Salon to give talk on Cannabis: Medicine, madness and Pleasure. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>56d70671a90238.72057346</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A new approach to European drug policy for the 21st century</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B071EA84-AF0C-4D0D-9651-4346EC8AD23A</gtr:id><gtr:impact>Talk sparked questions and discussions afterwards

Talk led to a visit to us in London by Madame Ruth Dreifuss (ex-President of Switzerland; member of the Global Drugs Commission)</gtr:impact><gtr:outcomeId>54609270be4978.52800310</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=ldQ53v37Y8U&amp;feature=youtu.be</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 4 PM - Talk on Cannabis and CBD trial (London)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>720B4273-FCD6-48C9-9C94-AA5ECD453A39</gtr:id><gtr:impact>Prof. Val Curran and Dr Tom Freeman talk about cannabis and the CBD clinical trial as part of Cannabis week on BBC Radio 4. http://www.bbc.co.uk/programmes/b05s310m</gtr:impact><gtr:outcomeId>56dd5cd0bfc5f9.92665702</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/science-environment-31518546</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture: The Intoxication Season at Kew Gardens - Cannabis: medicine or madness?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E624EAD0-FA1F-4DF4-BC4B-118811ED8FFA</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Public engagement activity - talk sparked questions and discussion afterwards from members of the public and Kew staff who attended.</gtr:impact><gtr:outcomeId>546097cb01aa14.77229487</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.kew.org/visit-kew-gardens/whats-on/intoxication-season</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute of Psychology Health and Society Departmental Seminar, University of Liverpool ( Liverpool, UK).</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5A137445-7239-4458-9D6E-A8AB434D19BB</gtr:id><gtr:impact>Presentation by TF on 'Can we reduce the harmful effects of cannabis?' at the Institute of Psychology Health and Society Departmental Seminar, University of Liverpool, UK, May 2014. Talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>58bd76f7431ff5.24602826</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Neuroscience Society (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D88F80C9-CBDD-4980-B71C-3F3CA284016A</gtr:id><gtr:impact>Presentation by HVC at UCL Neuroscience Society on Cannabis: pleasure, medicine, madness. 18/10/2016. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd6d45bdb3a2.05338179</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University College Hospital weekly Accident and Emergency meeting (UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1C0074DD-6091-4521-B264-CBCA08F320D5</gtr:id><gtr:impact>Presentation by TF on 'Cannabidiol: a novel intervention for cannabis use problems?' University College Hospital weekly Accident and Emergency meeting, UK, June 2014. Talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>58bd767379b658.84989363</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at 1st conference of the European Monitoring Centre for Drugs and Drug Addiction (Lisbon, Portugal)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C06F1BF9-EAD2-4BDE-94B1-6B839F798A5B</gtr:id><gtr:impact>Invited talk on Purple haze, Northern lightsneurocognitive effects of different strains of cannabis at 1st conference of the European Monitoring Centre for Drugs and Drug Addiction. Talk sparked questions and discussion afterwards</gtr:impact><gtr:outcomeId>56d705d7021235.86186092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.lisbonaddictions.eu/start</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Institute of Mental Health Clinical Academic Seminar (London)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B1D10AE1-C0F4-419E-97E2-C7AB9BB96BE1</gtr:id><gtr:impact>Presentation by HVC at UCL Institute of Mental Health on Cannabis: pleasure, madness, medicine. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd5fc2356a40.73073488</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker, American College of Neuropharmacology (ACNP), How does the THC and CBD content of cannabis influence its effects? (Miami, USA)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4381E5EF-D6B6-4605-B122-1723F59E26C9</gtr:id><gtr:impact>Invited speaker at American College of Neuropharmacology (ACNP) annual meeting. 1700 members and scientific guests in attendance. 
Talk on How does the THC and CBD content of cannabis influence its effects?</gtr:impact><gtr:outcomeId>58bd5c3f38ce17.78732420</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.acnp.org/default.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Hertfordshire. Talk on Cannabis and cannabinoids: mental health and medicines (Hertfordshire )</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>08D0AC09-9C44-4F6B-B039-67EC5947FCEA</gtr:id><gtr:impact>Presentation by HVC at University of Hertfordshire (16/02/2017) on Cannabis and cannabinoids: mental health and medicines. Talk sparked question and discussion afterwards</gtr:impact><gtr:outcomeId>58bd6cf3db5254.88062734</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newcastle University (Newcastle, UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0F9C92C4-BE78-4813-847F-95AADB05134E</gtr:id><gtr:impact>Talk by HVC at Newcastle University on Cannabis: pleasure, madness, medicine. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd6e938ef060.21878502</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture - Cannabis: pleasure, madness &amp; medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>20D6107B-B9E8-4813-9B42-F946B0CBAA69</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

N/A - public engagement activity</gtr:impact><gtr:outcomeId>546094bd19e1d2.84843553</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.scienceandcocktails.org/2014/Cannabis.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Neuroscience Association (Edinburgh, Scotland)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B19CFED2-B037-43EF-B9B3-AB57CDB88F9D</gtr:id><gtr:impact>Presentation by TF on 'Cannabis and addiction: cause, cure or both?' British Neuroscience Association, Edinburgh, April 2015. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd763a07aa13.75038888</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IEPA Early Intervention in Mental Health (Milan, Italy)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5CBCFC6-1AC1-4043-8BA5-D6B409FD2771</gtr:id><gtr:impact>Talk by TF on 'Comparing different types of cannabis on cognition, reward and addiction' at Early Intervention in Mental Health International Conference in Milan, Italy, October 2016. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd74c82d0580.97996813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Monitoring Centre for Drugs and Drug Addiction (Lisbon, Portugul)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>410A3CCC-42AF-42D3-B20E-BF95C4089D71</gtr:id><gtr:impact>Talk by TF on 'How can we optimise the treatment of people who are cannabis dependent?' European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Lisbon Addictions 2015.Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd75e9683aa8.34244538</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Psychosomatic Society 74th Annual Scientific Meeting (Denver, Colorado)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5FB39E42-DF9A-40D6-867E-2C02F2F3C1EB</gtr:id><gtr:impact>American Psychosomatic Society 74th Annual meeting in Denver, Colorado, USA. Plenary speaker on Cannabinoids and Cannabis Use Disorder. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd5d31d9ca71.25500693</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Association for Psychopharmacology Summer Meeting (Brighton, UK)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>69B1C263-7E6E-43D9-BCE5-FDA28EA3B5E6</gtr:id><gtr:impact>Talk by TF on 'Dissociable effects of cannabinoids on anticipatory and consummatory reward processing' at British Association for Psychopharmacology Summer Meeting, Brighton UK, July 2016. Talk sparked questions and discussion afterwards.</gtr:impact><gtr:outcomeId>58bd751b7a7de6.85302792</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk at American Psychosomatic Society annual meeting. Talk on Cannabinoids and cannabis use disorder</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>01C7D794-306F-41A7-802A-FAC71EB0C7D0</gtr:id><gtr:impact>Invited talk at American Psychosomatic Society annual meeting. Presentation on Cannabinoids and cannabis use disorder</gtr:impact><gtr:outcomeId>56d7049a26d354.52799194</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.psychosomatic.org/AnMeeting/2016annualmeeting.cfm</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary lecture - Pembroke-King's Programme (PKP)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4CBEC5CE-EE5B-4105-A57F-11F9FD58856C</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

N/A - public engagement activity</gtr:impact><gtr:outcomeId>546098cd8482d8.68371752</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:url>http://pembrokekings.wordpress.com/2014/07/21/pkp-plenary-lectures/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interview - Cannabis: Promise, risk and controversy</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>65FAA8E2-D1DF-41AF-8000-FD03BB545636</gtr:id><gtr:impact>Article on Cannabis: Promise, risk and controversy</gtr:impact><gtr:outcomeId>58c03485af6fb4.74800544</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/science-environment-31518546</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>148096</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Research Area Network on Illicit Drugs - IMAGEN Pathways</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Department of Health Social Services and Public Safety (DHSSPS)</gtr:fundingOrg><gtr:id>665EDA62-2AD2-4628-A474-E20B075FF43A</gtr:id><gtr:outcomeId>58bd579a670468.96347018</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244211</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Research Area Network on Illicit Drugs - ALAMA-nightlife</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Department of Health Social Services and Public Safety (DHSSPS)</gtr:fundingOrg><gtr:id>01CF7157-D75E-4796-BF18-96F0E1C77CCC</gtr:id><gtr:outcomeId>58bd56200c1218.61346212</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1620857</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council - Neurosciences &amp;amp; Mental Health Board</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P012728/1</gtr:fundingRef><gtr:id>BD2762A1-48EE-4E55-AB3D-BC4D0A53D705</gtr:id><gtr:outcomeId>58bd59b56a9173.49782567</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Beckley Foundation</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Beckley Foundation</gtr:fundingOrg><gtr:id>E6F74593-CB93-42DD-A824-0CE4907EC46D</gtr:id><gtr:outcomeId>54608fac9fd8a6.64235608</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Medical Association Margaret Temple Grant - Developing an endocannabinoid clinical model of schizophrenia: a multimodal pharmacological imaging study</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>DF4A20B0-B2DA-4276-80B9-E69D667826E0</gtr:id><gtr:outcomeId>58c02f2bb91ba6.64932840</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Independent Scientific Committee on Drugs</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>DrugScience</gtr:fundingOrg><gtr:id>6A743C89-9EF1-4B13-8292-0E0F1411D48A</gtr:id><gtr:outcomeId>ppb7bwAuVSW</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>All Party Parliamentary Committee on Drug Policy Reform, House of Lords. 'The case for rescheduling cannabis under the medicines act'</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E028984A-4AF4-4D50-B8EF-5CD05695A63E</gtr:id><gtr:outcomeId>58bd6f8d0dae40.24129154</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1883E735-BD8B-4959-BBCA-54F7098C60CF</gtr:id><gtr:title>Salience attribution and its relationship to cannabis-induced psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413ae84d0e24f0badbf8a45ff98faf7f"><gtr:id>413ae84d0e24f0badbf8a45ff98faf7f</gtr:id><gtr:otherNames>Bloomfield MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58bfdd95ecca33.82454687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>949216E2-C888-4139-9B4D-CCBEA4C49592</gtr:id><gtr:title>Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e214e19bbf02017e68d12e972df1e55"><gtr:id>0e214e19bbf02017e68d12e972df1e55</gtr:id><gtr:otherNames>Hindocha C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>56c497fe54d6c8.96323280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63111A4A-5184-4200-9FF4-CBCA1307CEAE</gtr:id><gtr:title>Keep off the grass? Cannabis, cognition and addiction.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a086a2eb787e9fe404d71084e9e0b7a"><gtr:id>1a086a2eb787e9fe404d71084e9e0b7a</gtr:id><gtr:otherNames>Curran HV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>58a47f4a723cd8.51624296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A470CE4-DD23-4A7C-956D-759625155D42</gtr:id><gtr:title>Cannabis potency: the need for global monitoring.</gtr:title><gtr:parentPublicationTitle>Addiction (Abingdon, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4ad1a624540e3dfb13ba77aa179d8c"><gtr:id>8e4ad1a624540e3dfb13ba77aa179d8c</gtr:id><gtr:otherNames>Freeman TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0965-2140</gtr:issn><gtr:outcomeId>58bd718c34c0c6.87402084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7502C9EF-B767-477F-AA6C-30985678FD3E</gtr:id><gtr:title>Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e332395aee7efb406665de4a514e85e1"><gtr:id>e332395aee7efb406665de4a514e85e1</gtr:id><gtr:otherNames>Mokrysz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>56c494b13c42f8.49648791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A202E8C6-8AC5-4AB0-985F-77C99CB5F40A</gtr:id><gtr:title>Rethinking dose-response effects of cannabis use in adolescence</gtr:title><gtr:parentPublicationTitle>The Lancet Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e9a0bba947702815a0f599ea1687ebc"><gtr:id>9e9a0bba947702815a0f599ea1687ebc</gtr:id><gtr:otherNames>Freeman T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a363d62c0a2.62099660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEAC92A1-2674-4F55-A0E3-65499F0232AC</gtr:id><gtr:title>Associations between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis users in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Drug and alcohol dependence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e214e19bbf02017e68d12e972df1e55"><gtr:id>0e214e19bbf02017e68d12e972df1e55</gtr:id><gtr:otherNames>Hindocha C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0376-8716</gtr:issn><gtr:outcomeId>56c49761681de0.58329550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB5CF676-418F-423E-9CF3-63E11FD3D3A1</gtr:id><gtr:title>Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review.</gtr:title><gtr:parentPublicationTitle>JAMA psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2cc2bd37e32aba039e1e2e73d24dfce"><gtr:id>f2cc2bd37e32aba039e1e2e73d24dfce</gtr:id><gtr:otherNames>Volkow ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-622X</gtr:issn><gtr:outcomeId>56c494b10cc2a5.77277142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECA87E15-20A4-404E-9732-FCF7D98F5BB9</gtr:id><gtr:title>Emotional processing deficits in chronic cannabis use: a replication and extension.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e214e19bbf02017e68d12e972df1e55"><gtr:id>0e214e19bbf02017e68d12e972df1e55</gtr:id><gtr:otherNames>Hindocha C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>545a304cec47c2.96015738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AC0D10E-5CE7-4E25-9160-C7BBC45A7A9D</gtr:id><gtr:title>Examining the profile of high-potency cannabis and its association with severity of cannabis dependence.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e4ad1a624540e3dfb13ba77aa179d8c"><gtr:id>8e4ad1a624540e3dfb13ba77aa179d8c</gtr:id><gtr:otherNames>Freeman TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>58bd718c82d937.94148292</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K015524/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>